Home Diagnostics, Inc. (Nasdaq:HDIX), a leading manufacturer and
marketer of diabetes testing supplies, today announced financial
results for the third quarter ended September 30, 2009.
Total revenue for the third quarter was $34.5 million, a
decrease of 3.0% from $35.6 million in the third quarter of 2008.
Retail channel sales increased 8.3%, driven by the continued
national rollout of the TRUEresult® and TRUE2go™ blood glucose
monitoring systems and an expanded product offering at Walmart.
Mail service channel sales increased 14.4% as a result of the
continued success of the private label, no-code blood glucose
system offered through Liberty Medical and our other mail service
providers who promote the TRUEbalance™ no-code blood glucose
system. Distribution channel sales decreased 16.9% as a result of
customers’ continued focus on reducing inventory days supply on
hand. International sales increased 19.8%, driven primarily by the
launch of TRUEbalance in several European markets.
Gross profit for the third quarter of 2009 was $17.9 million,
compared to $21.6 million in the third quarter of 2008. As a
percentage of sales, gross margin decreased to 51.8% compared to
60.8% in the prior year period. As the Company previously guided,
gross margin was negatively impacted by the continued investment in
the roll out of the new no-code products in the retail and mail
service channels. Gross margin was also impacted by lower pricing
in the mail service and distribution channels.
Selling, general and administrative expenses were $11.6 million
for the third quarter of 2009, compared with $13.4 million in the
third quarter of 2008. The decrease in selling, general and
administrative expenses was primarily due to lower sales and
marketing expenses following the initial launch of the TRUE2go and
TRUEresult systems last year and cost reduction initiatives.
Research and development expenses were $2.1 million for the
third quarter of 2009, compared with $2.0 million in the third
quarter of 2008.
Operating income for the third quarter of 2009 was $4.2 million,
compared to operating income of $6.2 million for the third quarter
of 2008.
For the three-month period ended September 30, 2009, the Company
reported net income of $2.9 million, or $0.17 per diluted share,
based on weighted average shares outstanding of 17.6 million. Net
income for the three-month period ended September 30, 2008 was $4.5
million, or $0.24 per diluted share, based on 18.8 million weighted
average shares outstanding.
Joseph Capper, President and Chief Executive Officer of Home
Diagnostics, said, “We are pleased with the results in the retail
and mail service channels, underscoring the success of our new
no-code products and marketing initiatives. Importantly, we
continue to gain domestic market share, driven by the demand for
our high-quality and value-priced blood glucose monitoring
TRUE-family of products. International business was up 20% for the
quarter. Our focus on operating cost controls contributed to solid
bottom line results. We are encouraged by increased demand for our
products reflected by record outsales in the distribution and
retail channels. Accordingly, we are on schedule to triple our
manufacturing capacity to support this growing demand for
TRUEtest™. This investment, along with a focus on well defined
strategic initiatives, positions us well to achieve sales growth in
all of our business channels in 2010.”
2009 Financial
Guidance
Based on the third quarter 2009 results and challenging market
conditions, specifically in the distribution channel, the Company
is adjusting its full year 2009 guidance. It now expects total
revenue to be in the range of $126 million to $127 million and
diluted earnings per share to be in the range of $0.30 to $0.32
from the previous estimate of $129 million to $131 million and
diluted earnings per share in the range of $0.36 to $0.38.
Conference Call
Home Diagnostics will hold a conference call on Thursday,
November 5, 2009 at 8:30 a.m. ET to discuss its operating results.
The dial-in numbers are 1-877-407-0789 for domestic callers and
1-201-689-8562 for international callers. A live Webcast of the
conference call will be available online from the investor
relations page of the Company’s corporate Website at
www.homediagnostics.com.
After the live Webcast, the call will remain available on Home
Diagnostics’ Website, www.homediagnostics.com, through December 5,
2009. In addition, a telephonic replay of the call will be
available until November 12, 2009. The replay dial-in numbers are
1-877-660-6853 for domestic callers and 1-201-612-7415 for
international callers. Please use account number 3055 and
conference ID number 334965.
About Home Diagnostics,
Inc.
Based in Fort Lauderdale, Florida, Home Diagnostics, Inc.
(NASDAQ: HDIX) is a leading developer, manufacturer and marketer of
diabetes management products. Home Diagnostics, Inc. offers a
portfolio of high-quality blood glucose monitoring systems that
spans the spectrum of features and benefits to help every person
with diabetes better monitor and manage their disease. The Home
Diagnostics, Inc. product line includes TRUE2go™, TRUEresult®,
TRUEtrack®, TRUEbalance™, Sidekick®, TRUEread® and Prestige IQ®
blood glucose monitoring systems. The products are available in
more than 45,000 pharmacies throughout the U.S. Home Diagnostics is
the exclusive co-brand supplier of blood glucose monitoring systems
for leading pharmacies including CVS, Rite Aid and Walgreens, as
well as distributors such as AmerisourceBergen, Cardinal Health,
McKesson, Invacare and Liberty Medical. Home Diagnostics, Inc. was
named one of Forbes magazine’s “200 Best Small Companies” in 2008,
and in 2009 received several recognitions for the company’s TRUE2go
blood glucose meter, including a Medical Design Excellence Award
(MDEA) and a Gold Award in the Medical/Test Equipment category as
part of appliance DESIGN Magazine’s 22nd Annual Excellence in
Design (EID) Awards Competition. For more information please visit
www.homediagnostics.com.
Forward-Looking
Statements
The above statements include forward-looking statements and are
subject to risks and uncertainties. Forward-looking statements give
the Company’s current expectations and projections relating to its
financial condition, results of operations, plans, objectives,
future performance and business. The statements can be identified
by the fact that they do not relate strictly to historical or
current facts. These statements may include words such as
“anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,”
“believe” and other words and terms of similar meaning in
connection with any discussion of the timing or nature of future
operating or financial performance or other events.
All statements other than statements of historical facts
included in this release that address activities, events or
developments that we expect, believe or anticipate will or may
occur in the future are forward-looking statements.
These forward-looking statements are largely based on our
expectations and beliefs concerning future events, which reflect
estimates and assumptions made by the Company’s management. These
estimates and assumptions reflect the Company’s best judgment based
on currently known market conditions and other factors relating to
the Company’s operations and business environment, all of which are
difficult to predict and many of which are beyond its control.
Although the Company believes its estimates and assumptions to
be reasonable, they are inherently uncertain and involve a number
of risks and uncertainties that are beyond the Company’s control.
In addition, management’s assumptions about future events may prove
to be inaccurate. Management cautions all readers that the
forward-looking statements contained in this release are not
guarantees of future performance, and the Company cannot assure any
reader that those statements will be realized or the
forward-looking events and circumstances will occur. Actual results
may differ materially from those anticipated or implied in the
forward-looking statements due to the factors listed in the “Risk
factors” and “Management’s discussion and analysis of financial
condition and results of operations” sections contained in its
filings with the Securities and Exchange Commission. All
forward-looking statements speak only as of the date of this
release. The Company does not intend to publicly update or revise
any forward-looking statements as a result of new information,
future events or otherwise, except as required by law. These
cautionary statements qualify all forward-looking statements
attributable to the Company or persons acting on its behalf.
TRUE2go, TRUEresult, TRUEbalance, TRUEtrack, Sidekick, TRUEread,
Prestige IQ, TRUEfill and TRUEtest are trademarks of Home
Diagnostics, Inc. All other trademarks are property of their
respective owners.
HOME
DIAGNOSTICS, INC. AND SUBSIDIARIES Consolidated Statements
of Operations (In thousands, except per share data)
(Unaudited) Three Months Ended Nine Months
Ended September 30, September 30, 2008
% of Sales 2009 % of
Sales 2008 % of Sales 2009
% of Sales Net sales $ 35,565 100.0 % $ 34,500
100.0 % $ 94,041 100.0 % $ 91,755 100.0 %
Cost of sales
13,936 39.2 % 16,616
48.2 % 37,937 40.3 %
44,973 49.0 %
Gross profit 21,629
60.8 % 17,884 51.8 %
56,104 59.7 % 46,782 51.0 %
Operating expenses: Selling, general and administrative
(including stock-based compensation expense of $665 and $522 and
$1,409 and $1,268 for the three and nine months ended September 30,
2008 and 2009, respectively) 13,400 37.7 % 11,594 33.6 % 38,969
41.4 % 36,277 39.6 % Research and development 2,035
5.7 % 2,051 5.9 % 6,819
7.3 % 5,905 6.4 % Total
operating expenses 15,435 43.4 %
13,645 39.5 % 45,788 48.7 %
42,182 46.0 %
Income from operations
6,194 17.4 % 4,239
12.3 % 10,316 11.0 % 4,600
5.0 %
Other income (expense): Interest income
(expense), net 231 0.7 % 10 0.0 % 773 0.8 % 75 0.1 % Other income
(expense), net (82 ) -0.2 % (31 )
-0.1 % (503 ) -0.6 % 107
0.1 % Other, net 149 0.5 % (21 )
-0.1 % 270 0.2 % 182
0.2 %
Income before provision for income taxes 6,343
17.9 % 4,218 12.2 % 10,586 11.2 % 4,782 5.2 % Provision for income
taxes 1,808 5.1 % 1,302
3.8 % 2,646 2.8 % 1,669
1.8 %
Net income $ 4,535 12.8 %
$ 2,916 8.4 % $ 7,940 8.4 % $
3,113 3.4 %
Earnings per common share: Basic $
0.26 $ 0.17 $ 0.45 $ 0.18 Diluted $ 0.24
$ 0.17 $ 0.42 $ 0.18
Weighted average
shares used in computing earnings per common share: Basic
17,610 16,894 17,783
17,031 Diluted 18,792 17,616
18,902 17,769
HOME DIAGNOSTICS, INC. AND SUBSIDIARIES
Supplemental Information (In thousands)
(Unaudited) December 31, September 30,
2008 2009 Selected Balance Sheet Data: Cash
and cash equivalents $ 30,367 $ 22,091 Working capital 44,005
41,421 Total assets 140,580 144,333 Total stockholders' equity
112,066 112,634
Three Months Ended September 30,
Nine Months Ended September 30, 2008
2009 2008
2009 Cash Flow Data: Cash provided by
operating activities $ 3,173 $ 4,205 $ 9,388 $ 5,683 Cash used in
investing activities (603 ) (2,388 ) (3,925 ) (10,110 ) Cash
provided by (used in) financing activities (2,430 ) 211 (3,873 )
(4,050 )
Revenue by Channel: Three Months
Ended September 30, 2008
2009 Increase/(Decrease)
Domestic: Retail $ 7,981 22.4 % $ 8,645 25.0 % $ 664 8.3 %
Distribution 18,802 52.9 % 15,620 45.3 % (3,182 ) -16.9 % Mail
Service 5,307 14.9 % 6,071
17.6 % 764 14.4 % Total Domestic 32,090 90.2 %
30,336 87.9 % (1,754 ) -5.5 % International 3,475
9.8 % 4,164 12.1 % 689
19.8 % Total $ 35,565 100.0 % $ 34,500
100.0 % $ (1,065 ) -3.0 %
Nine Months Ended September
30, 2008 2009
Increase/(Decrease) Domestic: Retail $ 20,536
21.8 % $ 25,585 27.9 % $ 5,049 24.6 % Distribution 48,010 51.1 %
39,646 43.2 % (8,364 ) -17.4 % Mail Service 14,897
15.8 % 17,116 18.6 % 2,219
14.9 % Total Domestic 83,443 88.7 % 82,347 89.7 % (1,096 )
-1.3 % International 10,598 11.3 %
9,408 10.3 % (1,190 ) -11.2 % Total $ 94,041
100.0 % $ 91,755 100.0 % $ (2,286 )
-2.4 %
[HDIX-F]
Home Diagnostics (MM) (NASDAQ:HDIX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Home Diagnostics (MM) (NASDAQ:HDIX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024